{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:53:14Z","timestamp":1761126794986,"version":"3.41.2"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination strategy. Here, we expressed monomeric and dimeric receptor-binding domains (RBDs) of the spike protein of prototype SARS-CoV-2 and Omicron variant in <jats:italic>E. coli<\/jats:italic> and investigated the reactivity of anti-sera from Chinese subjects immunized with SARS-CoV-2 vaccines to these recombinant RBDs. In 106 human blood samples collected from 91 participants from Jiangxi, China, 26 sera were identified to be positive for SARS-CoV-2 spike protein antibodies by lateral flow dipstick (LFD) assays, which were enriched in the ones collected from day 7 to 1 month post-boost (87.0%) compared to those harvested within 1 week post-boost (23.8%) (<jats:italic>P<\/jats:italic> &amp;lt; 0.0001). A higher positive ratio was observed in the child group (40.8%) than adults (13.6%) (<jats:italic>P<\/jats:italic> = 0.0073). ELISA results showed that the binding activity of anti-SARS-CoV-2 antibody-positive sera to Omicron RBDs dropped by 1.48- to 2.07-fold compared to its homogeneous recombinant RBDs. Thus, our data indicate that current SARS-CoV-2 vaccines provide restricted humoral protection against the Omicron variant.<\/jats:p>","DOI":"10.3389\/fimmu.2022.960195","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T14:24:44Z","timestamp":1659018284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Reduced binding activity of vaccine serum to omicron receptor-binding domain"],"prefix":"10.3389","volume":"13","author":[{"given":"Mingzhi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quansheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengle","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingdi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lumei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingbao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04399-5","article-title":"Activity of convalescent and vaccine serum against SARS-CoV-2 omicron","volume":"602","author":"Carreno","year":"2022","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.2022440","article-title":"Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost","volume":"11","author":"Ai","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103353","DOI":"10.1016\/j.ebiom.2021.103353","article-title":"Novel Japanese encephalitis virus NS1-based vaccine: Truncated NS1 fused with e. coli heat labile enterotoxin b subunit","volume":"67","author":"Wan","year":"2021","journal-title":"EBioMedicine"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3127","article-title":"Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors","volume":"33","author":"Wang","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2021.08.032","article-title":"Cellular OCIAD2 protein is a proviral factor for hepatitis c virus replication","volume":"188","author":"Yang","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-341941","article-title":"Autoreactive CD1b-restricted T cells: a new innate-like T-cell population that contributes to immunity against infection","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-405891-0.00001-5","article-title":"Chapter 1 - Introduction to big data","volume-title":"Data warehousing in the age of big data","author":"Krishnan","year":"2013"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41421-022-00380-8","article-title":"Landscape of the RBD-specific IgG, IgM, and IgA responses triggered by the inactivated virus vaccine against the omicron variant","volume":"8","author":"Xue","year":"2022","journal-title":"Cell Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00319-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1\/2 clinical trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.960195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T14:24:49Z","timestamp":1659018289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.960195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":11,"alternative-id":["10.3389\/fimmu.2022.960195"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.960195","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"960195"}}